This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of AQW051 in Patients With Memory Impairment

This study has been terminated.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 21, 2007
Last updated: April 15, 2016
Last verified: April 2016
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure cognitive function. This study will also explore the safety and tolerability of AQW051 in these patients.

Condition Intervention Phase
Mild Alzheimer's Disease Amnestic Mild Cognitive Impairment Drug: AQW051 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Validated computerized cognitive assessment scores [ Time Frame: Througout the study ]

Secondary Outcome Measures:
  • Validated computerized cognitive assessment scores, the different scores from the Alzheimer's Disease Assessment Score-cognitive subscale (ADAS-Cog), Quality of Life-Alzheimer disease scale and the Disability Assessment for Dementia scale [ Time Frame: Throughout the study ]

Enrollment: 54
Study Start Date: December 2007
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: AQW051
Placebo Comparator: 2 Drug: Placebo


Ages Eligible for Study:   55 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to give written informed consent
  • Meet the diagnostic criteria for either amnestic mild cognitive impairment (amnestic MCI) or mild Alzheimer's Disease (AD).
  • Structural brain scan within the last 6 months prior to randomization that indicates no other underlying disease, in particular no evidence for vascular pathology except for normal age-related white matter/incidental white matter changes which is normal for this age group.
  • Daily contact with a primary caregiver/partner

Exclusion Criteria:

  • Immune therapy targeting Alzheimer beta amyloid within the last 12 months
  • Institutionalized
  • Disability that may prevent completion of all study requirements (e.g., blindness, deafness, or communication difficulty)
  • Reported use of tobacco products in the previous 3 months or have a urine cotinine level greater than 500 ng/ml
  • Past medical history of clinically significant electrocardiogram (ECG) abnormalities or a family history (grandparents, parents, and siblings) of prolonged QT-interval syndrome
  • History or current diagnosis of conditions specified in the protocol.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00582855

Novartis Investigator Site
Halifax, Canada
Novartis Investigator Site
Montreal, Canada
Novartis Investigator Site
Toronto, Canada
South Africa
Novartis Investigator Site
Bloemfontein, South Africa
Novartis Investigator Site
George, South Africa
Novartis Investigator Site
Port Elizabeth, South Africa
United Kingdom
Novartis Investigator Site
Blackpool, United Kingdom
Novartis Investigator Site
Epping, United Kingdom
Novartis Investigator Site
Glasgow, United Kingdom
Novartis Investigator Site
Manchester, United Kingdom
Novartis Investigator Site
Southampton, United Kingdom
Novartis Investigator Site
Swindon, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT00582855     History of Changes
Other Study ID Numbers: CAQW051A2104
Study First Received: December 21, 2007
Last Updated: April 15, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Mild Alzheimer's disease
Amnestic Mild Cognitive Impairment

Additional relevant MeSH terms:
Alzheimer Disease
Cognition Disorders
Mild Cognitive Impairment
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on September 21, 2017